J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases
Executive Summary
Johnson & Johnson is instituting a best handling practices program for Eprex to reduce pure red cell aplasia associated with the product
You may also be interested in...
J&J Procrit Once-Weekly Labeling Resubmitted To FDA
Johnson & Johnson is hoping for approval of a supplemental BLA for once-weekly use of Procrit in chemotherapy patients by mid-2004
J&J Procrit Once-Weekly Labeling Resubmitted To FDA
Johnson & Johnson is hoping for approval of a supplemental BLA for once-weekly use of Procrit in chemotherapy patients by mid-2004
Aranesp Related To Four Cases Of PRCA, Far Below Eprex Rate, Amgen Says
Amgen is reporting four cases of pure red cell aplasia in Aranesp (darbepoetin alfa) patients